Citigroup Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Neurocrine Biosciences (NASDAQ:NBIX) had its target price upped by Citigroup from $203.00 to $204.00 in a report released on Thursday morning,Benzinga reports. Citigroup currently has a buy rating on the stock.

Several other research analysts have also weighed in on NBIX. BMO Capital Markets dropped their price target on Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating on the stock in a research report on Thursday. Stifel Nicolaus upped their target price on Neurocrine Biosciences from $183.00 to $188.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Morgan Stanley reissued an “equal weight” rating and issued a $175.00 price target (up from $173.00) on shares of Neurocrine Biosciences in a research report on Thursday, January 8th. Mizuho boosted their price objective on shares of Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, December 12th. Finally, HC Wainwright dropped their price objective on shares of Neurocrine Biosciences from $198.00 to $192.00 and set a “buy” rating on the stock in a research note on Thursday. Fifteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $177.56.

Neurocrine Biosciences Stock Down 10.4%

Shares of NASDAQ:NBIX opened at $123.10 on Thursday. The company’s fifty day moving average is $140.77 and its two-hundred day moving average is $140.46. The company has a market cap of $12.27 billion, a P/E ratio of 26.42, a price-to-earnings-growth ratio of 0.64 and a beta of 0.31. Neurocrine Biosciences has a 12-month low of $84.23 and a 12-month high of $160.18.

Insiders Place Their Bets

In related news, insider Darin Lippoldt sold 4,376 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $159.65, for a total transaction of $698,628.40. Following the completion of the sale, the insider owned 43,405 shares in the company, valued at $6,929,608.25. This represents a 9.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director George J. Morrow sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $143.37, for a total value of $2,150,550.00. Following the completion of the sale, the director directly owned 7,068 shares in the company, valued at $1,013,339.16. This trade represents a 67.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 61,966 shares of company stock valued at $8,625,166. 4.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Several hedge funds have recently modified their holdings of NBIX. Royal Bank of Canada increased its position in Neurocrine Biosciences by 36.7% during the first quarter. Royal Bank of Canada now owns 82,810 shares of the company’s stock worth $9,158,000 after acquiring an additional 22,224 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Neurocrine Biosciences by 60.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,783 shares of the company’s stock valued at $1,647,000 after purchasing an additional 5,577 shares during the period. NewEdge Advisors LLC grew its position in Neurocrine Biosciences by 56.3% in the 1st quarter. NewEdge Advisors LLC now owns 7,630 shares of the company’s stock worth $844,000 after purchasing an additional 2,747 shares during the last quarter. Empowered Funds LLC bought a new position in shares of Neurocrine Biosciences during the 1st quarter worth about $1,333,000. Finally, Geneos Wealth Management Inc. raised its position in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Analysts continue to show conviction in the long‑term story — several firms reiterated Buy/Outperform ratings and high price targets, signaling confidence in the Ingrezza franchise and pipeline potential. TipRanks: Bank of America reiterates Buy
• Positive Sentiment: Recent analyst upgrades/raises include Citigroup lifting its price target (to $204) and Wedbush nudging its target higher — evidence that some investors still see significant upside. Benzinga: Citi/Wedbush price target moves
• Positive Sentiment: Underlying commercial results were strong: full‑year 2025 net product sales and year‑over‑year revenue growth reinforce that Ingrezza remains a durable cash generator. PR Newswire: Q4 and FY2025 results
• Neutral Sentiment: Revenue came in roughly in line with expectations (~$805M), so top‑line growth isn’t the main driver of the decline — the market is reacting to profit/guidance details. MarketBeat: Earnings report & transcript
• Neutral Sentiment: Analyst reactions are mixed: several firms trimmed price targets modestly (RBC, BMO, Needham adjustments) while most maintained Buy/Outperform ratings — creates volatility but not a broad sell consensus. TipRanks: Mixed PT adjustments
• Negative Sentiment: EPS missed expectations — adjusted EPS reported below consensus — which, combined with cautious near‑term commentary, triggered selling pressure. MarketBeat: EPS miss details
• Negative Sentiment: Market commentary flagged “disappointing Ingrezza guidance” as a key catalyst for the decline — investors appear to have expected a stronger 2026 sales outlook. Benzinga: Analysts on Ingrezza guidance
• Negative Sentiment: Trading showed heavy volume and reports noted insider selling activity — both amplify downside momentum in the near term. QuiverQuant: Stock falls, insider selling

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.